DK2707003T3 - Krystallinske salte af (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacen-2-carboxylsyreamid og fremgangsmåder til anvendelse deraf - Google Patents

Krystallinske salte af (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacen-2-carboxylsyreamid og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK2707003T3
DK2707003T3 DK12782600.6T DK12782600T DK2707003T3 DK 2707003 T3 DK2707003 T3 DK 2707003T3 DK 12782600 T DK12782600 T DK 12782600T DK 2707003 T3 DK2707003 T3 DK 2707003T3
Authority
DK
Denmark
Prior art keywords
methyl
naphthacen
tetrahydroxy
octahydro
dioxo
Prior art date
Application number
DK12782600.6T
Other languages
Danish (da)
English (en)
Inventor
Catherine Coulter
Sean M Johnston
Farzaneh Seyedi
Original Assignee
Paratek Pharm Innc
Allergan Pharmaceuticals Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharm Innc, Allergan Pharmaceuticals Int Ltd filed Critical Paratek Pharm Innc
Application granted granted Critical
Publication of DK2707003T3 publication Critical patent/DK2707003T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C07C237/26Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C239/00Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
    • C07C239/08Hydroxylamino compounds or their ethers or esters
    • C07C239/20Hydroxylamino compounds or their ethers or esters having oxygen atoms of hydroxylamino groups etherified
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/40Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C07C2603/42Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
    • C07C2603/44Naphthacenes; Hydrogenated naphthacenes
    • C07C2603/461,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK12782600.6T 2011-05-12 2012-05-14 Krystallinske salte af (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacen-2-carboxylsyreamid og fremgangsmåder til anvendelse deraf DK2707003T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161485179P 2011-05-12 2011-05-12
PCT/US2012/037838 WO2012155146A1 (en) 2011-05-12 2012-05-14 Crystalline salts of (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide and methods of using the same

Publications (1)

Publication Number Publication Date
DK2707003T3 true DK2707003T3 (da) 2019-08-05

Family

ID=47139728

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12782600.6T DK2707003T3 (da) 2011-05-12 2012-05-14 Krystallinske salte af (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacen-2-carboxylsyreamid og fremgangsmåder til anvendelse deraf

Country Status (14)

Country Link
US (4) US9255068B2 (enExample)
EP (2) EP2707003B1 (enExample)
JP (5) JP6574572B2 (enExample)
CA (1) CA2835876C (enExample)
DK (1) DK2707003T3 (enExample)
ES (2) ES2739626T3 (enExample)
HR (1) HRP20191295T8 (enExample)
HU (1) HUE044536T2 (enExample)
LT (1) LT2707003T (enExample)
PL (1) PL2707003T3 (enExample)
PT (1) PT2707003T (enExample)
SI (1) SI2707003T1 (enExample)
TR (1) TR201911086T4 (enExample)
WO (1) WO2012155146A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8856782B2 (en) 2007-03-01 2014-10-07 George Mason Research Foundation, Inc. On-demand disposable virtual work system
US9098698B2 (en) 2008-09-12 2015-08-04 George Mason Research Foundation, Inc. Methods and apparatus for application isolation
WO2012155146A1 (en) * 2011-05-12 2012-11-15 Paratek Pharmaceuticals, Inc. Crystalline salts of (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide and methods of using the same
WO2013082437A1 (en) 2011-12-02 2013-06-06 Invincia, Inc. Methods and apparatus for control and detection of malicious content using a sandbox environment
JP2015517524A (ja) * 2012-05-14 2015-06-22 パラテック ファーマシューティカルズ インコーポレイテッド (4S,4aS,5aR,12aS)−4−ジメチルアミノ−3,10,12,12a−テトラヒドロキシ−7−[(メトキシ(メチル)アミノ)−メチル]−1,11−ジオキソ−1,4,4a,5,5a,6,11,12a−オクタヒドロ−ナフタセン−2−カルボン酸アミドの使用方法
ES2978198T3 (es) * 2016-10-19 2024-09-06 Tetraphase Pharmaceuticals Inc Formas cristalinas de eravaciclina
EP3654988B1 (en) * 2017-07-21 2023-09-06 Almirall, LLC Sarecycline for the treatment of non-inflammatory acne lesions
US12297161B2 (en) 2018-04-06 2025-05-13 Almirall, Llc Process for making sarecycline hydrochloride
EP4357798A4 (en) 2021-06-14 2025-05-21 Hioki E.E. Corporation SHORT-CIRCUIT DETECTION DEVICE AND SHORT-CIRCUIT DETECTION METHOD

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990331A (en) 1956-11-23 1961-06-27 Pfizer & Co C Stable solutions of salts of tetracyclines for parenteral administration
US2980584A (en) 1957-10-29 1961-04-18 Pfizer & Co C Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US3062717A (en) 1958-12-11 1962-11-06 Pfizer & Co C Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation
US3165531A (en) 1962-03-08 1965-01-12 Pfizer & Co C 13-substituted-6-deoxytetracyclines and process utilizing the same
US3454697A (en) 1965-06-08 1969-07-08 American Cyanamid Co Tetracycline antibiotic compositions for oral use
NL6607516A (enExample) 1966-05-31 1967-12-01
DE1767891C3 (de) 1968-06-28 1980-10-30 Pfizer Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat
US3957980A (en) 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
DE2442829A1 (de) 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
US4018889A (en) 1976-01-02 1977-04-19 Pfizer Inc. Oxytetracycline compositions
US4126680A (en) 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
CA2103189C (en) 1992-11-17 2005-05-03 Lorne M. Golub Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive collagen crosslinking during diabetes
US5834450A (en) 1994-02-17 1998-11-10 Pfizer Inc. 9- (substituted amino) -alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US6277061B1 (en) 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
ES2548261T3 (es) * 2006-12-21 2015-10-15 Paratek Pharmaceuticals, Inc. Derivados de tetraciclina para el tratamiento de infecciones bacterianas, virales y parasitarias
AU2007338681B2 (en) 2006-12-21 2013-09-26 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of inflammatory skin disorders
WO2009111064A2 (en) * 2008-03-05 2009-09-11 Paratek Pharmaceuticals, Inc. Minocycline compounds and methods of use thereof
TW202021946A (zh) * 2008-05-19 2020-06-16 美商派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
WO2012155146A1 (en) * 2011-05-12 2012-11-15 Paratek Pharmaceuticals, Inc. Crystalline salts of (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide and methods of using the same
JP2015517524A (ja) * 2012-05-14 2015-06-22 パラテック ファーマシューティカルズ インコーポレイテッド (4S,4aS,5aR,12aS)−4−ジメチルアミノ−3,10,12,12a−テトラヒドロキシ−7−[(メトキシ(メチル)アミノ)−メチル]−1,11−ジオキソ−1,4,4a,5,5a,6,11,12a−オクタヒドロ−ナフタセン−2−カルボン酸アミドの使用方法

Also Published As

Publication number Publication date
HRP20191295T8 (hr) 2020-02-07
JP6876082B2 (ja) 2021-05-26
US20200024223A1 (en) 2020-01-23
JP2019142867A (ja) 2019-08-29
US20160200671A1 (en) 2016-07-14
HRP20191295T1 (hr) 2019-10-18
ES2739626T3 (es) 2020-02-03
JP2023093519A (ja) 2023-07-04
EP2707003A4 (en) 2014-11-12
US9255068B2 (en) 2016-02-09
PT2707003T (pt) 2019-08-05
CA2835876A1 (en) 2012-11-15
SI2707003T1 (sl) 2019-10-30
TR201911086T4 (tr) 2019-08-21
EP2707003B1 (en) 2019-05-01
ES2985493T3 (es) 2024-11-06
LT2707003T (lt) 2019-10-10
PL2707003T3 (pl) 2019-11-29
EP2707003A1 (en) 2014-03-19
HUE044536T2 (hu) 2019-10-28
JP2014520077A (ja) 2014-08-21
EP3574908A1 (en) 2019-12-04
JP6574572B2 (ja) 2019-09-11
EP3574908B8 (en) 2024-09-11
CA2835876C (en) 2020-04-14
JP2017132775A (ja) 2017-08-03
US20130012480A1 (en) 2013-01-10
WO2012155146A1 (en) 2012-11-15
EP3574908B1 (en) 2024-07-31
US20190040002A1 (en) 2019-02-07
JP2021098695A (ja) 2021-07-01

Similar Documents

Publication Publication Date Title
DK2707003T3 (da) Krystallinske salte af (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacen-2-carboxylsyreamid og fremgangsmåder til anvendelse deraf
DK3238709T3 (da) Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme
DK2429417T3 (da) Apparat til påføring af kirurgisk fastgørelseselement
SMT201400142B (it) Composti di N-(1H-indazol-4-il) immidazo[1,2-A]piridin-3-carbossammide sostituita come inibitori di cfms
DK3170821T3 (da) Sammensætninger som indeholder, fremgangsmåder som involverer, og anvendelser af ikke-naturlige aminosyrebundne dolastatinderivater
DK2489670T3 (da) Fremgangsmåde til fremstilling af aminosyre-chelatforbindelser, aminosyre-chelatforbindelser og anvendelse af aminosyre-chelatforbindelser
BR112014000655A2 (pt) dispositivo magnético modular de anastomose
EP2670733A4 (en) HDAC HEMMER AND THERAPY PROCESS THEREFOR
DK2704703T3 (da) Transdermale sammensætninger af ibuprofen og fremgangsmåder til anvendelse deraf
EP2741703A4 (en) SURGICAL PLIERS
DK2451771T3 (da) Salte af rasagilin og farmaceutiske fremstillingsmåder heraf
EP2768854A4 (en) STABILIZED ETANERCEPT FORMULATIONS WITH AMINO ACIDS
SMT201600013B (it) Procedimento per la preparazione di acidi, esteri e ammidi [(3-idrossipiridin-2-carbonil) ammino]alcanoici
DK2583586T3 (da) Indretning til registrering af kollisioner og tilsvarende fremgangsmåde
BR112014001346A8 (pt) composto nanotransportador, método, composto farmacêutico e uso de um composto
DK2627233T3 (da) Fremgangsmåde til drift af en rengøringsindretning og rengøringsindretning til gennemførelse af fremgangsmåden
EP2418942A4 (en) NAPHTHALIN-BASED INHIBITORS OF ANTIAPOPTOTIC PROTEINS
EP2796461A4 (en) PROCESS FOR THE PRODUCTION OF ICOTINIB AND ICOTINIB HYDROCHLORIDE AND INTERMEDIATES THEREOF
DK2966058T3 (da) Nye calciumsalte af forbindelse som anti-inflammatoriske, immunomodulatoriske og anti-profliferative midler
DK2215050T3 (da) Fremgangsmåde til fremstilling af 2-hydroxy-5-phenylalkylaminobenzoesyrederivater og salte deraf
CL2013000797A1 (es) Proceso de preparacion de (2r,3r)-3-{4-(s-(ciclo)alquil-sulfonimidoil)fenil}amino}-5-(trifluorometil)pirimidin-4-il}oxi}butan-2-2ol inhibidores; y los compuestos intermediarios considerados.
EP2851010A4 (en) DEVICE FOR VASCULAR ANASTOMOSIS AND METHOD FOR VASCULAR ANASTOMOSIS
WO2013150545A8 (en) Process for preparation of benzimidazole derivatives and salts thereof
DK2486945T3 (da) Fremgangsmåde og indretning til rengøring af medicinske instrumenter
PL2758371T3 (pl) Nowe tiopochodne niosące laktamy jako silne inhibitory hdac i ich zastosowania jako leki